Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was ...
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...
3d
Hosted on MSNEllsworth woman raising awareness to rare neuromuscular diseaseA woman from Ellsworth is navigating life with a rare neuromuscular disease. Tina Bruning learned of her diagnosis of ...
Objective Patients with myasthenia gravis without acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) antibodies detected by radioimmunoprecipitation assays (RIAs) are classified as ...
Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a critical juncture in its growth trajectory as it advances its product ...
Post-treatment, all patients exhibited satisfactory improvements. The Myasthenia Gravis Foundation of America Quantitative Myasthenia Gravis (MGFA-QMG) scores, 15-item Myasthenia Gravis Quality of ...
The waiver, announced by Secretary of State Marco Rubio, seemed to allow for the distribution of H.I.V. medications, but whether the waiver extended to preventive drugs or other services offered ...
Structural derivatives of macrolide antibiotics, ketolides are erythromycin ... It also is contraindicated in patients with myasthenia gravis (Medical Economics, 2005). The most common side ...
Doctors are sounding the alarm about a common antibiotic taken by millions that is linked to a number of deaths and extreme reactions. Taken by about 3million Americans every year, Bactrim is ...
Pain reduction is one of the main signs that your UTI is going away. Pain generally eases within a couple of days of antibiotic treatment. Worsening pain in the lower abdomen or lower back are signs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results